Fig. 1 · Structure

Documents & Downloads

Ipratropium bromide

Cat. No. A10476 CAS 22254-24-6
Ipratropium bromide is a muscarinic antagonist, bronchodilator, N-Isopropyl salt of atropine.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Ipratropium bromide bound muscarinic receptor populations in rat cerebral cortex, heart and salivary-gland membranes, with reported Ki values of 1.24±0.36, 3.54±1.27 and 0.64±0.06 nM, respectively (mean±s.e.mean). These native-tissue assays support activity at M1-, M2- and M3-associated populations; they do not establish selective binding to M3. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
mAChR

Cellular Effect

Cell Line Activity Value Description Reference
CHO-K1 IC50 1.7 nM Displacement of [3H]NMS from human M3 receptor expressed in CHOK1 cell membranes after 4 hrs by scintillation counting method [PMID: 25800115]
CHO-K1 IC50 2 nM Displacement of [3H]NMS from human M2 receptor expressed in CHOK1 cell membranes after 4 hrs by scintillation counting method [PMID: 25800115]
CHO-K1 IC50 2.07 nM Displacement of [3H]NMS from human muscarinic M3 receptor expressed in CHOK1 cells by microplate scintillation counting [PMID: 19653626]
CHO-K1 IC50 2.24 nM Displacement of [3H]NMS from human muscarinic M2 receptor expressed in CHOK1 cells by microplate scintillation counting [PMID: 19653626]
CHO-K1 IC50 2.65 nM Displacement of [3H]NMS from human muscarinic M1 receptor expressed in CHOK1 cells by microplate scintillation counting [PMID: 19653626]
CHO-K1 IC50 2.9 nM Displacement of [3H]NMS from human M1 receptor expressed in CHOK1 cell membranes after 4 hrs by scintillation counting method [PMID: 25800115]

Ipratropium bromide Research Summary

This section summarizes 4 in vitro studies and 1 in vivo study of Ipratropium bromide from 2 published references. In vitro models include Wistar rat cerebral cortex, heart and salivary-gland membranes.

Ipratropium bromide In Vitro Studies

In isolated guinea-pig trachea, ipratropium bromide inhibited electrically evoked cholinergic contraction with an IC50 of 0.58 nM. At 10 nM, the washout half-recovery time was 81.2±3.7 min, compared with 26.4±0.5 min for glycopyrrolate (mean±s.e.mean). [1]

With carbachol-induced contraction in a separate guinea-pig tracheal study, ipratropium showed a pIC50 of 8.6±0.02 and a washout half-recovery time of 0.5±0.1 h (mean±s.e.m.). At 10 nM it did not inhibit neurokinin A-induced tone. The relative duration versus glycopyrrolate differed from the EFS experiment, so duration should remain tied to the assay conditions. [2,1]

In isolated human bronchial rings precontracted with carbachol, ipratropium produced a pIC50 of 9.5±0.04. After washout of 10 nM ipratropium, the response reached 50% recovery at 3.0±0.2 h and 110±10% recovery at 6 h (mean±s.e.m.). It did not inhibit neurokinin A-induced tone at 10 nM. These are tissue-bath findings from surgical specimens. [2]

Muscarinic receptor binding in rat tissue membranes

Biochemical assay · Wistar rat cerebral cortex (M1-enriched), heart (M2-enriched) and salivary-gland (M3-enriched) membranes. [1]

Ipratropium bromide competed for radioligand binding at all three tissue-defined receptor populations. These are native-tissue affinity measurements, not cloned human receptor subtype measurements.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Competition with [3H]-telenzepine in rat cerebral cortexKi 1.24±0.36 nM[1]
Competition with [3H]-NMS in rat heartKi 3.54±1.27 nM[1]
Competition with [3H]-NMS in rat salivary glandsKi 0.64±0.06 nM[1]

Literature-Reported Treatment Conditions

Exposure duration
2.5–3 h incubation at 30°C
Method
Competitive radioligand binding; native tissue membranes.
Vehicle
25 mM Tris buffer, pH 7.4; ipratropium stock solvent not specified in the read Drugs section.
Co-treatment
None; glycopyrrolate was a separate comparator.
Reported limits
Ipratropium competitor concentration range and hydration/stereochemical composition are not specified in the read assay text; no range inferred from the glycopyrrolate-only Figure 5.
Methods and source locations

Compound reported in the paper: Ipratropium bromide; Compound label in the paper: ipratropium bromide / ipratropium

Reported ipratropium bromide experiments only; no Adooq lot validation, salt conversion or clinical dose extrapolation.

Table 1 (image); Methods: Radioligand binding studies; Drugs and chemicals; Results: Selectivity of glycopyrrolate for M1–M3 receptors

Competition with [3H]-telenzepine in rat cerebral cortex: 0.4 nM radioligand; 30°C, 2.5–3 h; 1 μM atropine defined nonspecific binding. Mean±s.e.mean of 4–6 independent experiments performed in duplicate on separate membrane preparations. — Table 1, ipratropium bromide row, cerebral cortex; Methods: Binding assays

Competition with [3H]-NMS in rat heart: 0.3 nM radioligand; same binding assay controls and replication semantics as Table 1. — Table 1, ipratropium bromide row, heart; Methods: Binding assays

Competition with [3H]-NMS in rat salivary glands: 0.3 nM radioligand; same binding assay controls and replication semantics as Table 1. — Table 1, ipratropium bromide row, salivary glands; Methods: Binding assays

Inhibition and washout of nerve-evoked guinea-pig tracheal contraction

Cell-based study · Epithelium-denuded isolated tracheal strips from male Dunkin–Hartley guinea-pigs (250–500 g). [1]

Ipratropium bromide inhibited electrically evoked cholinergic contraction. At 10 nM, recovery after washout was slower than for glycopyrrolate in this EFS assay.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
50% inhibition of EFS-induced cholinergic contractionIC50 0.58 nM; n=6[1]
Time to 50% inhibition after antagonist additiont1/2 (onset) 7.6±1.2 min; n=5[1]
Time to 50% recovery of cholinergic contraction after washoutt1/2 (offset) 81.2±3.7 min; n=5[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 nM for onset/washout; concentration–response assay reported separately.
Exposure duration
Until maximal inhibition, followed by washout and repeat EFS to 50% recovery; fixed exposure duration not reported.
Method
Isometric tension in organ baths at 37°C; four stable EFS responses before antagonist addition.
Vehicle
Krebs–Henseleit solution; ipratropium stock solvent not specified in read Drugs section.
Co-treatment
No therapeutic combination; indomethacin 10 μM throughout, propranolol 1 μM before experiment, capsaicin 10 μM pretreatment followed by washout. Glycopyrrolate in separate preparations.
Reported limits
Exact concentration series was not tabulated; no points digitized. Reported n is animal-based in captions.
Methods and source locations

Compound reported in the paper: Ipratropium bromide; Compound label in the paper: ipratropium bromide / ipratropium

Reported ipratropium bromide experiments only; no Adooq lot validation, salt conversion or clinical dose extrapolation.

Figures 1–2 and captions; Results: Functional characteristics in guinea-pig trachea; Methods: Guinea-pig trachea and Statistical analysis

50% inhibition of EFS-induced cholinergic contraction: EFS at 4 Hz, 40 V, 0.5 ms, 15 s every 4 min; fitted concentration–inhibition curve. Exact IC50 from Results text, not read from graph. — Results: Potency of antagonists in inhibiting contractile responses to EFS; Figure 1

Time to 50% inhibition after antagonist addition: 10 nM ipratropium; mean±s.e.mean. Values interpolated by authors from time-effect curves. — Results: Time course for antagonists, guinea-pig; Figure 2A; Statistical analysis

Time to 50% recovery of cholinergic contraction after washout: 10 nM ipratropium; mean±s.e.mean; glycopyrrolate 10 nM comparator: 26.4±0.5 min, n=3. Appropriate antagonist-free time controls were included. — Results: Time course for antagonists, guinea-pig; Figure 2B; Methods: Protocol

Reversal and recovery of carbachol-induced guinea-pig tracheal contraction

Cell-based study · Isolated tracheal preparations from male albino Dunkin–Hartley guinea-pigs, 450–550 g. [2,1]

Ipratropium reversed carbachol-induced contraction, followed by recovery after washout. It did not relax neurokinin A-induced tone at the tested concentration.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
50% reversal of carbachol-induced tonic contractionpIC50 8.6±0.02[2]
Time to 50% recovery of carbachol response after antagonist washoutt1/2 (offset) 0.5±0.1 h[2]
Recovery of initial response to carbachol after washoutPercent recovery 70±7% at 4.5 h[2]
Relaxation of neurokinin A-induced smooth-muscle toneNegative specificity control No inhibition at 10 nM; n=4[2]

Literature-Reported Treatment Conditions

Treatment concentration
10 nM for washout and neurokinin A controls; cumulative concentration–response for pIC50.
Exposure duration
Antagonist maintained until complete and sustained relaxation; carbachol challenges for 4.5 h after washout.
Method
Isometric tension at 37°C; 0.3 μM carbachol precontraction; isoprenaline 0.3 μM as maximal inhibitory reference; matched vehicle-treated preparations.
Vehicle
10 mM stock in 100% DMSO, diluted with saline; organ-bath Krebs–Henseleit solution. A 1% DMSO-in-saline control was inactive.
Co-treatment
None; glycopyrrolate and tiotropium tested separately.
Reported limits
Exact ipratropium contact time and final in-vitro DMSO percentage are not specified in the read methods. Table n is observations, not necessarily independent donors/animals.
Methods and source locations

Compound reported in the paper: Ipratropium bromide; Compound label in the paper: ipratropium bromide / ipratropium

Reported ipratropium bromide experiments only; no Adooq lot validation, salt conversion or clinical dose extrapolation.

Table 1; Figure 2 and caption; Methods: tissue preparation, antagonist potency/offset; Chemicals; corresponding Results; Results: guinea-pig EFS time course; Figure 2B

50% reversal of carbachol-induced tonic contraction: −log10 molar IC50; mean±s.e.m., at least four observations. Cumulative antagonist curve on preparations precontracted with 0.3 μM carbachol. — Table 1, ipratropium row, guinea-pig trachea; Figure 2A

Time to 50% recovery of carbachol response after antagonist washout: 10 nM ipratropium; mean±s.e.m., at least four observations; repeated carbachol challenges at 45 min intervals. — Table 1 and footnotes; Figure 2B

Recovery of initial response to carbachol after washout: Mean±s.e.m., at least four observations; Figure 2 caption gives four to six observations. Recovery values can exceed 100% and are not percent inhibition. — Table 1, ipratropium row; Figure 2B

Relaxation of neurokinin A-induced smooth-muscle tone: Neurokinin A 1 μM; Results explicitly reports data not shown. This negative control supports stimulus-dependent action. — Results: Duration of antimuscarinic activity in the guinea-pig isolated trachea; neurokinin A control paragraph

Reversal and recovery of carbachol-induced human bronchial contraction

Cell-based study · Epithelium-denuded isolated human bronchial rings (1–5 mm internal diameter), macroscopically normal tissue from six lung-cancer surgery patients (four males), ages 48–66 years. [2]

Ipratropium reversed carbachol-induced contraction, followed by recovery after washout. It did not relax neurokinin A-induced tone at the tested concentration.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
50% reversal of carbachol-induced tonic contractionpIC50 9.5±0.04[2]
Time to 50% recovery of carbachol response after antagonist washoutt1/2 (offset) 3.0±0.2 h[2]
Recovery of initial response to carbachol after washoutPercent recovery 110±10% at 6.0 h[2]
Relaxation of neurokinin A-induced smooth-muscle toneNegative specificity control No inhibition at 10 nM; n=4[2]

Literature-Reported Treatment Conditions

Treatment concentration
10 nM for washout and neurokinin A controls; cumulative concentration–response for pIC50.
Exposure duration
Antagonist maintained until complete and sustained relaxation; carbachol challenges for 6.0 h after washout.
Method
Isometric tension at 37°C; 1 μM carbachol precontraction; isoprenaline 0.3 μM as maximal inhibitory reference; matched vehicle-treated preparations.
Vehicle
10 mM stock in 100% DMSO, diluted with saline; organ-bath Krebs–Henseleit solution. A 1% DMSO-in-saline control was inactive.
Co-treatment
None; glycopyrrolate and tiotropium tested separately.
Reported limits
Exact ipratropium contact time and final in-vitro DMSO percentage are not specified in the read methods. Table n is observations, not necessarily independent donors/animals.
Methods and source locations

Compound reported in the paper: Ipratropium bromide; Compound label in the paper: ipratropium bromide / ipratropium

Reported ipratropium bromide experiments only; no Adooq lot validation, salt conversion or clinical dose extrapolation.

Table 1; Figure 3 and caption; Methods: tissue preparation, antagonist potency/offset; Chemicals; corresponding Results

50% reversal of carbachol-induced tonic contraction: −log10 molar IC50; mean±s.e.m., at least four observations. Cumulative antagonist curve on preparations precontracted with 1 μM carbachol. — Table 1, ipratropium row, human bronchus; Figure 3A

Time to 50% recovery of carbachol response after antagonist washout: 10 nM ipratropium; mean±s.e.m., at least four observations; repeated carbachol challenges at 60 min intervals. — Table 1 and footnotes; Figure 3B

Recovery of initial response to carbachol after washout: Mean±s.e.m., at least four observations; Figure 3 caption gives four to six observations. Recovery values can exceed 100% and are not percent inhibition. — Table 1, ipratropium row; Figure 3B

Relaxation of neurokinin A-induced smooth-muscle tone: Neurokinin A 1 μM; Results explicitly reports data not shown. This negative control supports stimulus-dependent action. — Results: Duration of antimuscarinic activity in the human isolated bronchus; neurokinin A control paragraph

Ipratropium bromide In Vivo Studies

In an anaesthetized guinea-pig acetylcholine-challenge model, Table 2 reports that intratracheal ipratropium at 1.45 nmol kg−1 inhibited bronchoconstriction by 88.1±9.6% at the 15-min peak, 28.3±4.8% at 3 h and 14.2±5.6% at 24 h (mean±s.e.m.; 4–7 animals per group). The 24 h endpoint used a separate cohort. Both later values were lower than peak (P<0.01). The study’s figure labels use 1.5 nmol kg−1 for the high-dose group; the numeric summary here follows Table 2. [2]

Time course of bronchoprotection after intratracheal ipratropium

Animal study · Male albino Dunkin–Hartley guinea-pigs (450–550 g); anaesthetized ACh-challenge model; separate recovered animals for the 24 h endpoint. [2]

Ipratropium produced substantial early inhibition of acetylcholine-induced bronchoconstriction, with reduced protection at 3 and 24 h. The 24 h response was assessed in separate animals, not continuous repeated observations in the early cohort.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of ACh-induced bronchoconstriction at peak effectPercent inhibition 88.1±9.6% at 15 min[2]
Inhibition of ACh-induced bronchoconstriction 3 h after administrationPercent inhibition 28.3±4.8%; P<0.01 vs peak effect[2]
Residual inhibition of ACh-induced bronchoconstriction 24 h after administrationPercent inhibition 14.2±5.6%; P<0.01 vs peak effect[2]

Conditions shared by the study groups

Route
Intratracheal instillation
Frequency
Single administration
Treatment course
Early readouts at peak and 3 h; separate cohort for 24 h
Vehicle
DMSO final concentration ≤0.3% in saline; 1% DMSO control was ineffective.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Ipratropium, Table 2 dose
1.45 nmol kg−1 (Table 2)
Predrug ACh response for early cohort; time-matched vehicle-treated animals for residual-effect cohort; histamine challenge to verify reactivity at the end of late experiments.Peak at 15 min: 88.1±9.6%; 3 h: 28.3±4.8%; 24 h: 14.2±5.6% inhibition. Means±s.e.m., 4–7 animals group−1; latter two P<0.01 vs peak in Table 2.[2]
Ipratropium, Table 2 dose
Model: Male albino Dunkin–Hartley guinea-pigs (450–550 g); anaesthetized ACh-challenge model; separate recovered animals for the 24 h endpoint.
Reported limits: Table 2 reports 1.45 nmol kg−1, whereas Figures 4C and 5 label the corresponding high-dose ipratropium group 1.5 nmol kg−1. No explanation is given in the read text; selected numeric outcomes and dose are attributed strictly to Table 2.
Methods and source locations

Compound reported in the paper: Ipratropium bromide; Compound label in the paper: ipratropium bromide / ipratropium

Reported ipratropium bromide experiments only; no Adooq lot validation, salt conversion or clinical dose extrapolation.

Table 2 and footnotes; Figures 4C and 5 and captions; Methods: In vivo study; Chemicals

Inhibition of ACh-induced bronchoconstriction at peak effect: Table 2 dose: 1.45 nmol kg−1 intratracheally. ACh 20 μg kg−1 i.v.; response assessed by tidal-volume reduction relative to pre-drug response. Mean±s.e.m., 4–7 animals group−1. — Table 2, ipratropium row; Methods: In vivo study

Inhibition of ACh-induced bronchoconstriction 3 h after administration: Mean±s.e.m., 4–7 animals group−1. Table 2 dose: 1.45 nmol kg−1. — Table 2, ipratropium row and ** footnote

Residual inhibition of ACh-induced bronchoconstriction 24 h after administration: Separate recovered cohort; time-matched vehicle controls. Mean±s.e.m., 4–7 animals group−1. Table 2 dose: 1.45 nmol kg−1. — Table 2, ipratropium row and ** footnote; Methods: residual inhibitory activity protocol

Ipratropium, Table 2 dose · Table 2 and footnotes; Methods: early and residual-effect protocols; Figures 4C/5 dose-label difference

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 22254-24-6
Formula C20H30BrNO3
Molecular Weight 412.37
Synonyms Atrovent; Apovent; Aerovent
SMILES
CC(C)[N+]1(C2CCC1CC(C2)OC(=O)C(CO)C3=CC=CC=C3)C.[Br-]

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 75 mg/mL (181.87 mM)
Water 75 mg/mL (181.87 mM)
Ethanol 75 mg/mL (181.87 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Ipratropium bromide Research References

  1. [1] Haddad EB, Patel H, Keeling JE, et al. Pharmacological characterization of the muscarinic receptor antagonist, glycopyrrolate, in human and guinea-pig airways. British Journal of Pharmacology (1999). PMID: 10385241 DOI: 10.1038/sj.bjp.0702573 Source material
  2. [2] Villetti G, Bergamaschi M, Bassani F, et al. Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea-pig and human airways. British Journal of Pharmacology (2006). PMID: 16565730 DOI: 10.1038/sj.bjp.0706724 Source material

Added to your cart

View Cart Checkout
Loading...